CA3190786A1 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- CA3190786A1 CA3190786A1 CA3190786A CA3190786A CA3190786A1 CA 3190786 A1 CA3190786 A1 CA 3190786A1 CA 3190786 A CA3190786 A CA 3190786A CA 3190786 A CA3190786 A CA 3190786A CA 3190786 A1 CA3190786 A1 CA 3190786A1
- Authority
- CA
- Canada
- Prior art keywords
- indazol
- acrylamide
- disease
- fluoro
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013731.1 | 2020-09-01 | ||
| GBGB2013731.1A GB202013731D0 (en) | 2020-09-01 | 2020-09-01 | Novel cmpounds |
| PCT/GB2021/052262 WO2022049377A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3190786A1 true CA3190786A1 (en) | 2022-03-10 |
Family
ID=72749727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3190786A Pending CA3190786A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12497359B2 (https=) |
| EP (1) | EP4208448B1 (https=) |
| JP (1) | JP7784431B2 (https=) |
| CN (1) | CN116096712B (https=) |
| AU (1) | AU2021336750A1 (https=) |
| CA (1) | CA3190786A1 (https=) |
| GB (1) | GB202013731D0 (https=) |
| IL (1) | IL300904A (https=) |
| WO (1) | WO2022049377A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202013728D0 (en) * | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel compounds |
| GB202300833D0 (en) | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| CN121866248A (zh) | 2023-09-05 | 2026-04-14 | Nrg治疗有限公司 | 作为mptp抑制剂起作用的吡啶衍生物 |
| CN118255724A (zh) * | 2024-03-27 | 2024-06-28 | 河北天成药业股份有限公司 | 盐酸利多卡因杂质的合成方法及其反应检测方法 |
| GB202410534D0 (en) | 2024-07-18 | 2024-09-04 | Nrg Therapeutics Ltd | Novel method and uses |
| CN120025281A (zh) * | 2025-04-22 | 2025-05-23 | 九洲药业(杭州)有限公司 | 一种n,n-二异丁基-1h-吲唑-4-胺的中间体及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1424078A4 (en) | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT |
| WO2003051876A1 (en) | 2001-12-14 | 2003-06-26 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| US7482488B2 (en) | 2002-08-29 | 2009-01-27 | Temple University - Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| EP1960355A1 (en) * | 2005-11-30 | 2008-08-27 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles and aza-substituted indoles |
| US7915304B2 (en) | 2006-10-24 | 2011-03-29 | Congenia S.R.L. | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT |
| EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| WO2011087051A1 (ja) | 2010-01-14 | 2011-07-21 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 |
| CA2884607A1 (en) | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
| WO2019002624A1 (de) | 2017-06-30 | 2019-01-03 | Kleuser, Burkhard | Mittel zur therapie entzündlicher darmerkrankungen |
| GB202013728D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel compounds |
-
2020
- 2020-09-01 GB GBGB2013731.1A patent/GB202013731D0/en not_active Ceased
-
2021
- 2021-09-01 IL IL300904A patent/IL300904A/en unknown
- 2021-09-01 AU AU2021336750A patent/AU2021336750A1/en not_active Abandoned
- 2021-09-01 CN CN202180053586.6A patent/CN116096712B/zh active Active
- 2021-09-01 WO PCT/GB2021/052262 patent/WO2022049377A1/en not_active Ceased
- 2021-09-01 EP EP21769790.3A patent/EP4208448B1/en active Active
- 2021-09-01 CA CA3190786A patent/CA3190786A1/en active Pending
- 2021-09-01 JP JP2023537724A patent/JP7784431B2/ja active Active
- 2021-09-01 US US18/023,488 patent/US12497359B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4208448A1 (en) | 2023-07-12 |
| IL300904A (en) | 2023-04-01 |
| US12497359B2 (en) | 2025-12-16 |
| EP4208448B1 (en) | 2025-04-23 |
| GB202013731D0 (en) | 2020-10-14 |
| CN116096712B (zh) | 2026-03-17 |
| JP7784431B2 (ja) | 2025-12-11 |
| JP2023539695A (ja) | 2023-09-15 |
| CN116096712A (zh) | 2023-05-09 |
| US20230312466A1 (en) | 2023-10-05 |
| WO2022049377A1 (en) | 2022-03-10 |
| AU2021336750A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4208448B1 (en) | Acrylamide derivatives | |
| EP4208442B1 (en) | Mptp inhibitors | |
| EP2997023B9 (en) | Bipyrazole derivatives as jak inhibitors | |
| HK1245769A1 (en) | Bipyrazole salt as jak inhibitor | |
| WO2023166303A1 (en) | Acrylamide compounds | |
| KR20250134200A (ko) | mPTP 억제제 | |
| WO2021062036A1 (en) | Jak inhibitors | |
| CN121866248A (zh) | 作为mptp抑制剂起作用的吡啶衍生物 | |
| HK40103736A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40049209B (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40049209A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40012259B (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40012259A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK1221466B (en) | Bipyrazole derivatives as jak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240828 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240828 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240828 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250815 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250819 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250825 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250825 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251003 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251003 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251003 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251103 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251103 |